BioVie Inc.

AI-generated fair value estimate for this company.

Method: Net cash per share plus modest risk-adjusted pipeline optionality: $8.71M net cash ($8.98M cash less $0.28M debt) divided by 7.54M shares equals a $1.16/share cash floor, plus a roughly 40% optionality premium for ongoing Phase 3 NE3107 trials in Parkinson's and Alzheimer's, heavily discounted for high clinical-trial failure risk and a thin (roughly 5-6 month) cash runway implying near-term dilutive financing.

Reasoning: BioVie is a pre-revenue clinical-stage biotech, so a standard FCF DCF does not apply; a net-cash floor plus discounted pipeline optionality is the more appropriate framework, and the heavy discount reflects both binary trial-outcome risk and the imminent need for additional capital given the current burn rate.